Microbiota Dysbiosis in Amyotrophic Lateral Sclerosis: A Systematic Review of Human Studies
- 7 November 2025
- journal article
- review article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 1-13
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration. Despite intensive research, its pathogenesis remains poorly understood. Recent insights suggest a pivotal role of the gut microbiota in modulating neuroinflammation and neurodegeneration via the gut-brain axis. This systematic review aims to synthesize clinical evidence on gut microbiota dysbiosis in ALS, exploring microbial and metabolic alterations and their associations with disease progression and severity. A comprehensive literature search was conducted across PubMed, Embase, Scopus, Web of Science, and other databases up to May 10, 2024, adhering to PRISMA 2020 guidelines. Eighteen eligible human studies were selected based on predefined inclusion criteria. Data on microbial diversity, taxonomic shifts, metabolite profiles, and clinical correlations were extracted and assessed using a modified Newcastle–Ottawa Scale. Most studies reported altered microbial diversity, reduced butyrate-producing bacteria (e.g., Faecalibacterium, Roseburia), and increased pro-inflammatory taxa (e.g., Escherichia coli, Bacteroides) in ALS. Integrated microbiome–metabolome analyses revealed disruptions in SCFAs, bile acids, and lipid metabolism, some correlating with ALSFRS-R scores and cognitive impairment. Although some studies showed minimal or no differences, the overall evidence supports a link between dysbiosis and ALS pathophysiology. Probiotic trials demonstrated limited efficacy, highlighting the need for targeted, patient-specific interventions. Gut microbiota dysbiosis is increasingly recognized as a contributor to ALS progression. However, methodological variability, small sample sizes, and limited longitudinal data restrict definitive conclusions. Future research should employ standardized, multi-omics approaches and larger cohorts to clarify causal links and develop microbiome-informed diagnostics and therapies for ALS. Graphical AbstractKeywords
This publication has 34 references indexed in Scilit:
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s diseasenpj Parkinson's Disease, 2024
- The effects of the interplay between vitamins, antibiotics, and gut microbiota on the pathogenesis and progression of dementia: A systematic review and meta‐analysisHealth Science Reports, 2024
- Current understanding of the Alzheimer’s disease-associated microbiome and therapeutic strategiesExperimental & Molecular Medicine, 2024
- Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic reviewJournal of Neurology, 2023
- Amyotrophic lateral sclerosisThe Lancet, 2022
- Rummeliibacillus suwonensis: First Time Isolation from Human Feces by CulturomicsCurrent Microbiology, 2022
- Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?Acta Neuropathologica, 2018
- The fecal microbiome of ALS patientsNeurobiology of Aging, 2018
- The gut microbiota — masters of host development and physiologyNature Reviews Microbiology, 2013
- Amyotrophic lateral sclerosisThe Lancet, 2011